Christoph Höner zu Siederdissen

Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B

Christoph Höner zu Siederdissen, Franziska Rinker, Benjamin Maasoumy et al. · The Journal of Infectious Diseases · 2016 · 139 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +17

Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B

Franziska Rinker, Christine L. Zimmer, Christoph Höner zu Siederdissen et al. · Journal of Hepatology · 2018 · 138 citations

Pharmacy, Immunology, Infectious Diseases +12

Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels

Milan J. Sonneveld, Shao‐Ming Chiu, Jun Yong Park et al. · Journal of Hepatology · 2022 · 122 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Improvement of liver function parameters in advanced <scp>HCV</scp> ‐associated liver cirrhosis by <scp>IFN</scp> ‐free antiviral therapies

Katja Deterding, Christoph Höner zu Siederdissen, Kerstin Port et al. · Alimentary Pharmacology & Therapeutics · 2015 · 120 citations · Full text

Medicine, Infectious Diseases, Pharmacology +17

Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)

Milan J. Sonneveld, Jun Yong Park, Apichat Kaewdech et al. · Clinical Gastroenterology and Hepatology · 2020 · 103 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17